机构地区:[1]State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060,Guangdong,P.R.China [2]Department of Cancer Prevention Research,Sun Yat-sen University Cancer Center,651 Dongfeng Road East,Guangzhou 510060,Guangdong,P.R.China [3]School of Public Health,Sun Yat-sen University,Guangzhou 510060,Guangdong,P.R.China [4]Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510060,Guangdong,P.R.China [5]Department of Experimental Research,Sun Yat-sen University Cancer Center,651 Dongfeng Road East,Guangzhou 510060,Guangdong,P.R.China [6]Sihui Cancer Institute,Sihui 526200,Guangdong,P.R.China
出 处:《Cancer Communications》2018年第1期81-94,共14页癌症通讯(英文)
基 金:supported by the National Key R&D Program of China(No.2016YF0902000 and No.2017YF0907100 to S.C.);the National Natural Science Foundation of China(No.81373068 to S.C.,and No.81672872,No.81272340 and No.81472386 to C.Q.);National Key Research and Development Program of China(No.2014BAI09B and No.2016YFC0902001 to S.C.);the Science and Technology Planning Project of Guangdong Province,China(No.2014B020212017,No.2014B050504004 and No.2015B050501005 to C.Q.);the Provincial Natural Science Foundation of Guangdong,China(No.2016A030311011 to C.Q.).
摘 要:Background:The association of circulating inflammation markers with nasopharyngeal carcinoma(NPC)is still largely unclear.This study aimed to comprehensively explore the relationship between circulating cytokine levels and the subsequent risk of NPC with a two-stage epidemiologic study in southern China.Methods:The serum levels of 33 inflammatory cytokines were first measured in a hospital-based case-control study(150 NPC patients and 150 controls)using multiplex assay platforms.Marker levels were categorized into two or more groups based on the proportion of sample measurements that was above the lower limit of detection.Odds ratios(ORs)and 95%confidence intervals(CIs)relating the serum marker concentration to the risk of NPC were computed by multivariable logistic regression models.The associations were validated in 60 patients with NPC and 120 con-trols in a subsequent nested case-control study within a NPC screening trial.Potential interactions between serum cytokines and Epstein-Barr virus(EBV)relating to the risk of NPC were assessed using a likelihood ratio test.Results:The levels of serum macrophage inflammatory protein(MIP)-1αand MIP-1βin the highest categories were associated with a decreased risk of NPC in both the case-control study(MIP-1α:OR=0.49,95%CI=0.26-0.95;MIP-1β:OR=0.47,95%CI=0.22-1.00)and the nested case-control study(MIP-1α:OR=0.13,95%CI=0.03-0.62;MIP-1β:OR=0.20,95%CI=0.04-0.94),compared with those in the lowest categories.Furthermore,individuals with lower levels of these two cytokine markers who were EBV seropositive presented with a largely higher risk of NPC compared with patients with higher levels who were EBV seronegative in both the case-control study(MIP-1α:OR=16.28,95%CI=7.11-37.23;MIP-1β:OR=12.86,95%CI=5.9-28.05)and the nested case-control study(MIP-1α:OR=86.12,95%CI=10.58-701.03;MIP-1β:OR=115.44,95%CI=13.92-957.73).Conclusions:Decreased preclinical MIP-1αand MIP-1βlevels might be associated with a subsequently increased risk of NPC.More mechanistic studies are require
关 键 词:Nasopharyngeal carcinoma Prospective study Inflammatory cytokine Macrophage inflammatory protein Epstein-Barr virus
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...